Biomarkers for Alzheimer's disease can be trusted in clinical trials

The best-established biomarkers for Alzheimer’s disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimer’s disease.

The results are presented by researchers at the Sahlgrenska Academy at Göteborg University, Sweden, in the November 2007 issue of the Journal of Alzheimer’s Disease.

“We show that the best-established diagnostic biomarkers for Alzheimer’s disease stay at basically the same level during two years in patients with early Alzheimer’s disease. This means that the biomarkers could be useful for detecting even minor biochemical changes induced by treatment in the clinical trials of novel drugs against Alzheimer’s," says Henrik Zetterberg, Associate Professor at the Sahlgrenska Academy.

Dr Zetterberg and colleagues analyzed cerebrospinal fluid from more than 80 patients with mild cognitive impairment. Some of these patients developed full-blown Alzheimer’s disease. The measured levels of the tau and amyloid-B proteins were compared in samples drawn from the same patients two years apart.

“If a novel drug candidate actually stops or slows down the neurodegenerative disease process in Alzheimer's disease, we should expect a normalized tau concentration in cerebrospinal fluid in patients on active treatment. Such a change should be readily detectable also in a small and inexpensive pilot study, given the low intra-individual variation in biomarker levels over time that was detected in our study," Dr Zetterberg says.

Alzheimer's disease is an age-related brain-damaging disorder that results in progressive cognitive impairment and death. Three decades of progress have resulted in a profound understanding of the molecular mechanisms underlying the disease. In the past 10 years, this knowledge has translated into a range of targets for therapy, the most promising of which is amyloid-B.

Source: Swedish Research Council

Related stories:

New study finds healthy children of Alzheimer patients show early brain changes
Medical College of Wisconsin researchers in Milwaukee have reported that children of Alzheimer's patients who are carriers of a genetic risk factor for Alzheimer's disease have neurological changes that are detectable long before clinical symptoms may appear.
New Membrane Model May Unlock Secrets of Early-Stage Alzheimer's
Researchers at the National Institute of Standards and Technology and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
New criterion may improve identification of dementia risk in highly educated older adults
A different cutoff point on an existing mental function assessment may more effectively assess the risk of dementia in highly educated older adults, according to a report in the July issue of Archives of Neurology.
UQ-US team targets faster Alzheimer’s detection
Early detection of Alzheimer's Disease is in the sights of University of Queensland (UQ) scientists who have secured $1.6 million for new research.


Memory loss linked to common sleep disorder
For the first time, UCLA researchers have discovered that people with sleep apnea show tissue loss in brain regions that help store memory. Reported in the June 27 edition of the journal Neuroscience Letters, the findings emphasize the importance of early detection of the disorder, which afflicts an estimated 20 million Americans.
Gene variation linked to earlier onset of Alzheimer's symptoms
Investigators at Washington University School of Medicine in St. Louis have identified a genetic variation associated with an earlier age of onset in Alzheimer's disease.
Researchers clear up Alzheimer's plaques in mice
Blocking a common immune system response cleared up plaques associated with Alzheimer’s Disease and enabled treated mice to recover some lost memory, Yale University researchers report Friday in the journal Nature Medicine.

News discussion:

Medicine & Health news